阿扑吗啡皮下输注治疗伴持续运动波动的帕金森病患者(TOLEDO):一项多中心、双盲、随机、安慰剂对照试验
TOLEDO试验在23家欧洲医院纳入107例口服或透皮治疗优化后仍有运动波动的帕金森病患者,随机接受阿扑吗啡皮下输注(3-8 mg/h)或安慰剂生理盐水,每日清醒时16小时,共12周。阿扑吗啡组每日关期绝对变化为-2.47小时,安慰剂组为-0.58小时,组间差异-1.89小时/日(95%CI -3.16至-0.62;p=0.0025)。阿扑吗啡耐受良好,无意外安全信号;阿扑吗啡组6例因治疗相关不良事件退出。
要点
- 阿扑吗啡皮下输注较安慰剂显著减少帕金森病患者每日关期时间,差异-1.89小时/日(95%CI -3.16至-0.62;p=0.0025)。
- 阿扑吗啡组每日关期变化-2.47小时,安慰剂组-0.58小时,所用阿扑吗啡平均最终剂量4.68 mg/h(SD 1.50)。
- 阿扑吗啡耐受良好,无意外安全信号;阿扑吗啡组6例因治疗相关不良事件退出研究。
核心结论
- 阿扑吗啡输注可使口服或透皮治疗优化后仍有持续运动波动的帕金森病患者关期时间出现有临床意义的减少。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照试验,在23家欧洲医院入组107例帕金森病病程超过3年且运动波动未获充分控制的患者,按1:1随机分配接受阿扑吗啡3-8 mg/h或安慰剂生理盐水皮下输注,每日清醒时16小时(可接受范围14-18小时),共12周。
- 前4周可根据个体疗效和耐受性调整研究药物流速及其他口服药物,之后进入8周维持期;主要终点为基于患者日记的每日关期绝对变化,在意向治疗人群(full analysis set)中评估。
- 全分析集共106例(两组各53例);安全性在所有接受至少一剂阿扑吗啡或安慰剂的患者中评估;研究注册号ClinicalTrials.gov NCT02006121。
主要发现
- 阿扑吗啡组每日关期变化-2.47小时(SD 3.70),安慰剂组-0.58小时(SD 2.80),组间差异-1.89小时/日(95%CI -3.16至-0.62;p=0.0025)。
- 阿扑吗啡平均最终剂量为4.68 mg/h(SD 1.50)。
- 阿扑吗啡耐受良好,无意外安全信号;阿扑吗啡组6例因治疗相关不良事件退出研究。
局限性
- 本文仅报告12周双盲阶段结果,52周开放标签阶段结果未在本文报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Subcutaneous apomorphine infusion is a clinically established therapy for patients with Parkinson's disease with motor fluctuations not optimally controlled by oral medication. Open-label studies have shown that apomorphine infusion is effective in reducing off time (periods when antiparkinsonian drugs have no effect), dyskinesias, and levodopa dose, but confirmatory evidence from double-blind, controlled studies is lacking. We aimed to investigate the efficacy and safety of apomorphine infusion compared with placebo in patients with Parkinson's disease with persistent motor fluctuations despite optimised oral or transdermal treatment. METHODS: In this randomised, placebo-controlled, double-blind, multicentre trial, we enrolled patients at 23 European hospitals who had been diagnosed with Parkinson's disease more than 3 years previously and had motor fluctuations not adequately controlled by medical treatment. Patients were randomly assigned (1:1) with a computer-generated randomisation code, stratified by site, to receive 3-8 mg/h apomorphine or placebo saline infusion during waking hours (16 h a day [range 14-18 was acceptable]) for 12 weeks. The flow rate of the study drug and other oral medications could be adjusted during the first 4 weeks on the basis of individual efficacy and tolerability, after which patients entered an 8-week maintenance period. The primary endpoint was the absolute change in daily off time based on patient's diaries, and was assessed in the full analysis set, which was defined as all patients who received at least one dose of allocated study drug and had efficacy data available at any timepoint post-baseline. Safety was assessed in all patients who received at least one dose of apomorphine or placebo. All study participants and investigators were masked to treatment assignment. Both the 12-week double-blind phase and the 52-week open-label phase of this study are now complete; this paper reports results for the double-blind phase only. This study is registered with ClinicalTrials.gov (NCT02006121). FINDINGS: Between March 3, 2014, and March 1, 2016, 128 patients were screened for eligibility and 107 were randomly assigned, of whom 106 were included in the full analysis set (n=53 in both groups). Apomorphine infusion (mean final dose 4·68 mg/h [SD 1·50]) significantly reduced off time compared with placebo (-2·47 h per day [SD 3·70] in the apomorphine group vs -0·58 h per day [2·80] in the placebo group; difference -1·89 h per day, 95% CI -3·16 to -0·62; p=0·0025). Apomorphine was well tolerated without any unexpected safety signals. Six patients in the apomorphine group withdrew from the study because of treatment-related adverse events. INTERPRETATION: Apomorphine infusion results in a clinically meaningful reduction in off time in patients with Parkinson's disease with persistent motor fluctuations despite optimised oral or transdermal therapy. FUNDING: Britannia Pharmaceuticals.
引用
- Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018. PMID: 30055903. doi:10.1016/S1474-4422(18)30239-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。